SurroMed has promoted Christopher Becker and William Leschensky to vice president of chemistry and president of intellectual property, respectively.
Becker joined SurroMed as director of chemistry in 2001, after serving as senior director of proteomic technology at Thermo Electron, and previously, as a staff scientist at SRI. He received his PhD in chemistry at UC Berkeley. Leschensky has been director of intellectual property at SurroMed since 2000, and has also been associate general counsel. Before joining SurroMed, he was an associate at the law firm Fish & Neave. He received his MD from the University of Illinois and a law degree from Harvard Law School.
Serologicals has appointed Dennis Harris as chief scientific officer, vice president of research and development, and vice president of business development. He will also serve on the executive operating committee and as a corporate officer.
Harris, 47, comes to Serologicals from Vitra Biosciences. He has also worked for Amersham International, Molecular Dynamics, Amersham Pharmacia Biotech, and Aclara Biosciences. He earned BS and PhD degrees in biochemistry at the University of Sussex, UK.
has formed a new oncology scientific advisory board. It has named as chairman Paul Bunn, and as members Gail Eckhardt, Eric Rowinsky, and Daniel Von Hoff.
Bunn is the director of the University of Colorado Cancer Center, in Boulder, and previously served as president of the American Society of Clinical Oncology and chairman of the US Food and Drug Administration’s Oncology Drugs Advisory Committee. Bunn received his MD from Cornell University Medical College.
Eckhardt is a professor of medicine and the director of the developmental therapeutics and GI malignancies programs at the University of Colorado Health Science Center in Denver. She has previously served as associate director of clinical research, cancer therapy and the research center at the Institute for Drug Development in San Antonio, Texas. She received an MD from the University of Texas Medical Branch in Galveston.
Rowinsky is director of the Institute for Drug Development, Cancer Therapy and Research Center and clinical professor of medicine at the University of Texas Health Science Center at San Antonio, NaPro said.
Von Hoff is professor of medicine, pathology, molecular and cellular biology and the director of the Arizona Health Sciences Center cancer therapeutics program. He is also director of translational research at the Translational Genomics Research Institute, chief scientific officer for US Oncology, and a founder of ILEX Oncology. Von Hoff received his MD from Columbia University.
NaPro, of Boulder, Colo., is seeking diagnostic and therapeutic applications for its gene-editing technology in cancer.
Decode Genetics has appointed James Beery to its board of directors. Beery is senior of counsel in the London office of Covington & Burling, an international law firm. He comes to Decode’s board from GlaxoSmithKline, where he was senior vice president and general counsel. Beery holds a BA from Harvard College and a JD from Stanford Law School.